|
Showing 1 - 2 of
2 matches in All Departments
There is no field of medicine in which advances in therapy have
been so closely linked to a better understanding of molecular
medicine than in the area of hematologic malignancies. For example,
recent insights into the understanding of Epstein-Barr virus have
led to new treatment options for patients with posttransplant
lymphoproliferative disorders, as discussed in the chapter by Dr.
Richard Ambinder et al. Similarly, Drs. Slack and Gallagher discuss
the explosion of recent information regarding the molecular
pathogenesis of acute promyelocytic leukemia. This particular
morphologic subtype of acute my- eloid leukemia warrants separate
discussion because of our increased under- standing of the
pathogenesis of leukemia, as well as the dramatic advances in
outcome that have occurred with differentiation therapy provided by
the vitamin A derivative aW-trans retinoic acid, as discussed in
the chapter by Drs. Frankel and Powell. New approaches in the
therapy of diffuse aggressive lymphomas in relationship to
prognostic factors are discussed by Drs. Koc and Schenkein. Novel
approaches to cutaneous T-cell lymphomas are discussed by Drs. Foss
and Kuzel. Drs. Fonseca and Greipp discuss prognostic factors in
myeloma, which are potentially important since they may serve to
identify patients who may benefit from aggressive therapy such as
bone marrow trans- plantation, which is discussed in the chapter by
Dr. David Vesole. State-of-the-art reviews are provided in the
chapters on AIDS-related non- Hodgkin's lymphoma by Drs. Volm and
Von Roenn, adult acute lympho- blastic leukemia by Drs.
There is no field of medicine in which advances in therapy have
been so closely linked to a better understanding of molecular
medicine than in the area of hematologic malignancies. For example,
recent insights into the understanding of Epstein-Barr virus have
led to new treatment options for patients with posttransplant
lymphoproliferative disorders, as discussed in the chapter by Dr.
Richard Ambinder et al. Similarly, Drs. Slack and Gallagher discuss
the explosion of recent information regarding the molecular
pathogenesis of acute promyelocytic leukemia. This particular
morphologic subtype of acute my- eloid leukemia warrants separate
discussion because of our increased under- standing of the
pathogenesis of leukemia, as well as the dramatic advances in
outcome that have occurred with differentiation therapy provided by
the vitamin A derivative aW-trans retinoic acid, as discussed in
the chapter by Drs. Frankel and Powell. New approaches in the
therapy of diffuse aggressive lymphomas in relationship to
prognostic factors are discussed by Drs. Koc and Schenkein. Novel
approaches to cutaneous T-cell lymphomas are discussed by Drs. Foss
and Kuzel. Drs. Fonseca and Greipp discuss prognostic factors in
myeloma, which are potentially important since they may serve to
identify patients who may benefit from aggressive therapy such as
bone marrow trans- plantation, which is discussed in the chapter by
Dr. David Vesole. State-of-the-art reviews are provided in the
chapters on AIDS-related non- Hodgkin's lymphoma by Drs. Volm and
Von Roenn, adult acute lympho- blastic leukemia by Drs.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.